Xeris Biopharma Grants Fda Orphan-Drug Exclusivity For Recorlev
By, Admin1 min read
Share
Xeris Biopharma Holdings Announced That The Food And Drug Administration (Fda) Granted Its Subsidiary Xeris Pharmaceuticals Orphan-Drug Exclusivity (Ode) For Recorlev
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.
